Get started
Work

Abstract PS1-10-21: Switching CDK4/6 inhibitors due to Toxicity in first-line treatment of HR+/HER2- metastatic breast cancer: Incidence and Outcomes from the ESME Cohort

Year: 2026
Type: conference-abstract
DOI: 10.1158/1557-3265.sabcs25-ps1-10-21
Authors: T. Papazyan, A. Lusque, W. Jacot, T. Grinda, A. Mailliez, E. Brain, T. Bachelot, C. Levy, M. Arnedos, A. Goncalves, V. Massard, M. Mouret-reynier, T. De la Motte Rouge, T. Petit, A. Savoye, I. Desmoulins, M. Leheurteur, L. Bosquet, M. Campone, J. Frenel
Institutions: Institut Claudius Regaud, Institut Regional du Cancer de Montpellier, Institut Gustave Roussy, Centre Oscar Lambret, Institut Curie, Centre Léon Bérard, Centre François Baclesse, Institut Bergonié, Institut de Cancérologie de Lorraine, Centre Jean Perrin, Centre Eugène Marquis, Institut de Cancérologie Strasbourg, Centre Georges François Leclerc, UniCancer Group
Language: English
Field: Medicine
Open Access status: closed
OpenAlex ID: W7129445716
Cites:
Cited by:
Related to: